AMGN Relative Valuation
AMGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AMGN is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.00
P/B
Median3y
Median5y
0.00
FCF Yield
Median3y
Median5y
Competitors Valuation Multiple
The average P/S ratio for AMGN's competitors is 6.12, providing a benchmark for relative valuation. Amgen Inc Corp (AMGN) exhibits a P/S ratio of 4.30, which is -29.72% above the industry average. Given its robust revenue growth of 10.86%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Amgen Inc (AMGN) currently overvalued or undervalued?
What is Amgen Inc (AMGN) fair value?
How does AMGN's valuation metrics compare to the industry average?
What is the current P/B ratio for Amgen Inc (AMGN) as of Apr 28 2025?
What is the current FCF Yield for Amgen Inc (AMGN) as of Apr 28 2025?
What is the current Forward P/E ratio for Amgen Inc (AMGN) as of Apr 28 2025?